Biocon has potential to outperform pharma index: Vinith Jain

ET Now spoke to Vinith Jain, Director, Siddh Capital, for a fundamental check on Biocon.
What's the call on the Biocon stock?

Yes, the stock has moved into a multiyear high after breaking the resistance at 330. The stock looks very good for short term as well as medium-term long here and I even feel the stock has a potential to outperform the pharma index. I see a target of Rs 385 in the near future.